ÂÜÀòÂÒÂ×

Harold Shlevin is an experienced leader in the biotechnology and pharmaceutical sectors, currently serving as a Director on the Board of Galectin Therapeutics and as an Authorized Agent for the company. With a significant tenure that includes roles such as Chief Executive Officer and President at Galectin Therapeutics until 2020, Shlevin has also held leadership positions at companies like Cardiome Pharma Corp, NeurOp, Inc., and Tikvah Therapeutics, Inc. Additionally, Shlevin has contributed as a Principal at Chana Tikvah Pharma Consulting Partners and a Board Advisor at Moonlight Therapeutics. With a robust educational background in physiology and pharmacology, including a PhD from the University of Rochester, Shlevin possesses extensive expertise in strategic consulting, product development, and commercialization within the biotechnology field.